Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Fig. 1

Consort diagram of this study. In total, 79 patients with mCRC are enrolled in the study. Patient sera are used to measure PRTN3 levels with ELISA. Overall, 48 primary tumor and 5 liver tumor samples obtained surgically from the 79 patients are subjected to IHC staining. The prognostic impact and association with the efficacy of first-line chemotherapy of PRTN3 levels are examined. Flow cytometric analysis is performed using peripheral whole blood samples from 12 patients with mCRC. Abbreviations: IHC, immunohistochemistry; mCRC, metastatic colorectal cancer; PRTN3, proteinase-3

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us